Praxis Precision Medicines, Inc. PRAX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific expenses by Product | ||||||
| Elsunersen | $3.2M+26.1% | $2.54M+14.3% | $2.22M+68.5% | $1.32M+73.1% | $761K+38.6% | |
| Other early stage assets | $3.24M+37.7% | $2.36M-25.0% | $3.14M+122% | $1.42M+28.2% | $1.11M-20.6% | |
| Relutrigine | $12.85M-14.9% | $15.1M+0.9% | $14.97M+42.4% | $10.51M+95.4% | $5.38M+94.9% | |
| Ulixacaltamide | $19.1M+97.7% | $9.67M-17.0% | $11.64M-36.7% | $18.39M-21.8% | $23.51M-9.6% | |
| Vormatrigine | $20.49M-4.5% | $21.47M+2.7% | $20.9M+16.4% | $17.96M+30.8% | $13.73M+50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Praxis Precision Medicines, Inc. break its business down?
- Praxis Precision Medicines, Inc. (PRAX) reports program-specific expenses by product across 5 parts — Elsunersen, Other early stage assets, Relutrigine, Ulixacaltamide and Vormatrigine. Each is extracted from the segment footnotes and tracked over time.
- Where does Praxis Precision Medicines, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Praxis Precision Medicines, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.